uniQure N.V. (NASDAQ:QURE) belongs to Healthcare sector. Its weekly performance is -3.58%. On last trading day company shares ended up $25.30. uniQure N.V. (NASDAQ:QURE) distance from 50-day simple moving average (SMA50) is -11.01%. Roth Capital reaffirmed their buy rating on shares of Uniqure NV (NASDAQ:QURE) in a report issued on Monday, AnalystRatings.Net reports.
Ignyta, Inc. (NASDAQ:RXDX) shares advanced 0.86% in last trading session and ended the day at $15.17. RXDX return on assets is -59.50%. Ignyta, Inc. (NASDAQ:RXDX) quarterly performance is 41.12%. Ignyta, Inc. (NASDAQ:RXDX) announced a clinical collaboration with the University of California, San Francisco (UCSF), under which UCSF will study entrectinib in a proof-of-concept clinical trial in cancer patients with metastatic melanoma that is positive for activating alterations to NTRK1/2/3 (encoding TrkA/TrkB/TrkC) or ROS1.
On 09 July, Genesis Energy LP (NYSE:GEL) shares advanced 1.04% and was closed at $44.50. GEL EPS growth in last 5 year was 18.30%. Genesis Energy LP (NYSE:GEL) year to date (YTD) performance is 7.65%. Genesis Energy, L.P. (NYSE:GEL) announced that it will pay a regular quarterly distribution of $0.625 per Common Unit for the quarter ended June 30, 2015. The distribution will be paid on August 14, 2015, to Common Unitholders of record at the close of business on July 31, 2015.
Infosys Ltd. (NYSE:INFY) ended the last trading day at $15.41. Company weekly volatility is calculated as 1.49% and price to cash ratio as 6.99. Infosys Ltd. (NYSE:INFY) showed a weekly performance of -3.14%. Infosys Ltd. (NYSE:INFY) will now offer the Finacle suite of software solutions on Verizon Cloud as Software-as-a-service (SaaS) model.
Mylan N.V. (NASDAQ:MYL) shares increased 2.02% in last trading session and ended the day at $70.35. MYL Gross Margin is 46.50% and its return on assets is 5.10%. Mylan N.V. (NASDAQ:MYL) quarterly performance is 0.36%. Mylan N.V. (NASDAQ: MYL) announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant’s Targretin® Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.